LNP Solution (CEO Dabin Lee, LNP Solution), a company specializing in in-silico CRO services based on artificial intelligence (AI) and molecular modeling, announced that it has secured seed investment. This round was also participated by the AI Angel Club and CNT Tech's joint ventures, "AI Angel-CNT Tech Private Investment Fund No. 2" and "AI Angel Club Private Investment Fund No. 41."
L&P Solution is a technology company specializing in the discovery and optimization of new drug candidates, leveraging its in silico drug discovery platform technology that combines AI and molecular modeling. Key technological capabilities include virtual screening, molecular dynamics, reverse screening, and peptide and biologics modeling. Through active collaborations with domestic and international pharmaceutical companies and research institutions, L&P Solution is generating tangible research results.
Additionally, in June, we participated in the bio event 'BIO USA 2025' held in Boston, USA, and discussed cooperation plans with global companies.
Based on this seed investment, L&P Solution plans to advance its AI model and generative compound design technology, and accelerate the development of more precise prediction models and new drug candidate design technology by expanding its server equipment infrastructure.
Dabin Lee, CEO of L&P Solution, said, “With this successful investment in Sheet, we will continue to strengthen collaboration with domestic and international pharmaceutical companies and grow into an AI-based new drug development company that is attracting attention in the global market.”
You must be logged in to post a comment.